Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2026-05-14 Declaration of Voting R…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a Form 8-K current report under the U.S. Securities Exchange Act, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing the voting results at the company’s 2026 Annual General Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (code DVA).
2026-05-14 English
8-K/A - Mereo BioPharma Group plc (0001719714) (Filer)
Regulatory Filings Classification · 90% confidence The document is an SEC Form 8-K/A (amendment to a current report under the Exchange Act) correcting a tagging error and furnishing a press release as an exhibit. It is not the primary financial report itself, nor a proxy, earnings release (the press release is referenced only as an exhibit), management discussion, or investor presentation. It is a general regulatory filing under US securities law. Therefore, it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-12 English
10-Q - Mereo BioPharma Group plc (0001719714) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Mereo BioPharma Group plc (0001719714) (Filer)
Regulatory Filings Classification · 85% confidence The document is a United States SEC Form 8-K “Current Report” dated May 12, 2026, furnishing a press release on quarterly results as Exhibit 99.1. It is a regulatory filing under the Exchange Act rather than the primary earnings press release itself. Under our taxonomy, Form 8-K and similar compliance filings without substantial financial statements are classified as Regulatory Filings (RNS).
2026-05-12 English
ARS - Mereo BioPharma Group plc (0001719714) (Filer)
Annual Report
2026-04-09 English
DEF 14A - Mereo BioPharma Group plc (0001719714) (Filer)
Proxy Solicitation & Information Statement
2026-04-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.